ATE405271T1 - Pyrazoloä3,4-düpyrimidinderivate und ihre verwendung als antagonisten des purinergen rezeptors - Google Patents
Pyrazoloä3,4-düpyrimidinderivate und ihre verwendung als antagonisten des purinergen rezeptorsInfo
- Publication number
- ATE405271T1 ATE405271T1 AT02729443T AT02729443T ATE405271T1 AT E405271 T1 ATE405271 T1 AT E405271T1 AT 02729443 T AT02729443 T AT 02729443T AT 02729443 T AT02729443 T AT 02729443T AT E405271 T1 ATE405271 T1 AT E405271T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- group
- aryl
- nr6r7
- pyrazoloa3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100621.2A GB0100621D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds VI |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE405271T1 true ATE405271T1 (de) | 2008-09-15 |
Family
ID=9906568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02729443T ATE405271T1 (de) | 2001-01-10 | 2002-01-10 | Pyrazoloä3,4-düpyrimidinderivate und ihre verwendung als antagonisten des purinergen rezeptors |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7087754B2 (de) |
| EP (1) | EP1349552B1 (de) |
| JP (1) | JP2004517861A (de) |
| AT (1) | ATE405271T1 (de) |
| CA (1) | CA2433997A1 (de) |
| DE (1) | DE60228406D1 (de) |
| GB (1) | GB0100621D0 (de) |
| WO (1) | WO2002055082A1 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0207246D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| WO2004009602A1 (en) * | 2002-07-23 | 2004-01-29 | Smithkline Beecham Corporation | Pyrazolopyrimidines as kinase inhibitors |
| DE10238724A1 (de) * | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| DE10328479A1 (de) | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
| DE602004017654D1 (de) * | 2003-07-16 | 2008-12-18 | Janssen Pharmaceutica Nv | Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3 |
| EP2145888A1 (de) | 2003-09-18 | 2010-01-20 | Conforma Therapeutics Corporation | Deazapurinderivate als HSP90-Inhibitoren |
| AU2004283751B2 (en) * | 2003-10-24 | 2011-05-19 | Exelixis, Inc. | p70S6 kinase modulators and method of use |
| DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| MX2007011903A (es) | 2005-03-30 | 2007-12-05 | Conforma Therapeutics Corp | Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90. |
| WO2006126718A1 (ja) * | 2005-05-27 | 2006-11-30 | Tanabe Seiyaku Co., Ltd. | ピラゾロピリミジン誘導体 |
| WO2007023110A2 (en) * | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| EP2217602B1 (de) | 2007-11-30 | 2018-08-29 | Boehringer Ingelheim International GmbH | 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-on- derivative und ihre verwendung als pde9a modulatoren zur behandlung von erkrankungen des zns |
| US7886697B2 (en) * | 2007-12-06 | 2011-02-15 | Tima Foundation | Optimized oral glucose tolerance test |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| EP2789615B1 (de) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazole als BTK-Kinasemodulatoren und Verwendung davon |
| JP5756176B2 (ja) | 2010-08-12 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ６−シクロアルキル−１，５−ジヒドロ−ピラゾロ（３，４−ｄ）ピリミジ−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| HRP20170430T1 (hr) | 2012-06-13 | 2017-06-16 | Incyte Holdings Corporation | Supstituirani triciklični spojevi kao inhibitori fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| PL2986610T4 (pl) | 2013-04-19 | 2019-06-28 | Incyte Holdings Corporation | Bicykliczne heterocykle jako inhibitory FGFR |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MY197720A (en) | 2015-02-20 | 2023-07-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2018079988A1 (ko) * | 2016-10-26 | 2018-05-03 | 울산과학기술원 | Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물 |
| JP7071389B2 (ja) * | 2017-03-07 | 2022-05-18 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | アミノピリミジン縮合５員複素環化合物、その中間体、製造方法、薬物組成物および使用 |
| CN121159691A (zh) | 2017-05-12 | 2025-12-19 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
| DE102017125533A1 (de) * | 2017-10-31 | 2019-05-02 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| CN108864114B (zh) * | 2018-06-04 | 2020-11-06 | 应世生物科技(南京)有限公司 | 选择性a2a受体拮抗剂 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| MX2021003554A (es) | 2018-09-25 | 2021-05-27 | Harpoon Therapeutics Inc | Proteinas de union a dll3 y metodos de uso. |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7675711B2 (ja) | 2019-10-14 | 2025-05-13 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20210061202A (ko) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| US11806350B2 (en) * | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| EP4352060A1 (de) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclische heterocyclen als fgfr-inhibitoren |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN116589464B (zh) * | 2022-02-14 | 2025-10-31 | 上海科技大学 | 嘧啶并环类化合物、其制备方法和应用 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA902280B (en) * | 1989-03-29 | 1990-12-28 | Merrell Dow Pharma | Selective adenosine receptor agents |
| AU690527B2 (en) * | 1992-12-17 | 1998-04-30 | Pfizer Inc. | Pyrazoles having CRF antagonist activity |
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
-
2001
- 2001-01-10 GB GBGB0100621.2A patent/GB0100621D0/en not_active Ceased
-
2002
- 2002-01-10 US US10/250,952 patent/US7087754B2/en not_active Expired - Fee Related
- 2002-01-10 CA CA002433997A patent/CA2433997A1/en not_active Abandoned
- 2002-01-10 JP JP2002555816A patent/JP2004517861A/ja active Pending
- 2002-01-10 WO PCT/GB2002/000075 patent/WO2002055082A1/en not_active Ceased
- 2002-01-10 EP EP02729443A patent/EP1349552B1/de not_active Expired - Lifetime
- 2002-01-10 DE DE60228406T patent/DE60228406D1/de not_active Expired - Lifetime
- 2002-01-10 AT AT02729443T patent/ATE405271T1/de not_active IP Right Cessation
-
2006
- 2006-01-12 US US11/275,525 patent/US7629349B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7629349B2 (en) | 2009-12-08 |
| DE60228406D1 (de) | 2008-10-02 |
| GB0100621D0 (en) | 2001-02-21 |
| JP2004517861A (ja) | 2004-06-17 |
| WO2002055082A1 (en) | 2002-07-18 |
| US7087754B2 (en) | 2006-08-08 |
| EP1349552A1 (de) | 2003-10-08 |
| EP1349552B1 (de) | 2008-08-20 |
| US20060111373A1 (en) | 2006-05-25 |
| US20040116447A1 (en) | 2004-06-17 |
| CA2433997A1 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE405271T1 (de) | Pyrazoloä3,4-düpyrimidinderivate und ihre verwendung als antagonisten des purinergen rezeptors | |
| PE20040893A1 (es) | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| AR035548A1 (es) | Compuestos organicos | |
| EA200600364A1 (ru) | Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| DE60129210D1 (de) | Zyklische amid-derivate | |
| CO5080780A1 (es) | Derivado de amida y antagonista de nociceptina | |
| CA2613226A1 (en) | Inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| HRP20070328T3 (hr) | SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI | |
| PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
| HUP0303146A2 (hu) | Protein kináz gátló hatású 3-(4-amido-pirrol-2-il-metilidén)-2-indolinon származékok és ezeket tartalmazó gyógyszerkészítmények | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| TR200400185T4 (tr) | PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri. | |
| DK419086A (da) | Heterocykliske substituerede indoler, mellemprodukter, fremgangsmaader til fremstilling heraf og laegemidler | |
| HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
| TW200745034A (en) | New compounds | |
| SE0201937D0 (sv) | Therapeutic agents | |
| CY1108632T1 (el) | Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας | |
| EA200500717A1 (ru) | Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |